Skip to main content

Table 2 Response and survival in all 19 patients

From: A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma

Arm

Stage

ELISPOT response (Y/N/NE)

Best response

No. of cycles completed

Time on trial (months)

Months alive from trial start

A

M

Y

SD

8

3.7

9.4

A

M

N

PD

4

1.8

15.9

A

M

N

SD

24

11.1

47.2*

A

NED

N

SD

24

12.4

32.4*

A

NED

N

SD

24

12.2

31.9*

B

M

Y

PD

4

1.9

3.1

B

M

Y

SD

23

12

43.2*

B

M

Y

PD

3

1.4

3.6

B

M

N

SD

22

10

?*

B

M

N

PD

4

1.8

2.2

B

M

NE

PD

1

0.3

0.4

B

M

NE

PD

4

1.2

1.5

B

M

NE

PD

4

1.8

3.0

C

M

Y

PD

4

1.9

11.3

C

LA

Y

CR

81

39.3

75.4*

C

M

Y

PD

4

1.8

11.0

C

M

Y

SD

12

6.2

48.5*

C

M

NE

PD

3

1.2

2.0

C

M

NE

PD

3

1.4

2.6

  1. Abbreviations: NED = No evidence of disease; M = metastatic; LA = locally advanced; Y = Yes; N = No; NE = not evaluable; * = currently alive; ? = patient is known to be alive but had withdrawn consent; Data as of May 22, 2012.